TrialAnnals of surgical oncology2024

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015).

Daisaku Yamada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.